Evox Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Evox Therapeutics's estimated annual revenue is currently $13.5M per year.
- Evox Therapeutics's estimated revenue per employee is $102,000
- Evox Therapeutics's total funding is $169.2M.
Employee Data
- Evox Therapeutics has 132 Employees.
- Evox Therapeutics grew their employee count by -13% last year.
Evox Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | VP CMC | Reveal Email/Phone |
2 | Director Intellectual Property | Reveal Email/Phone |
3 | Associate Research Director (AAV) | Reveal Email/Phone |
4 | Senior Director Operations | Reveal Email/Phone |
5 | Senior Director Translational Medicine | Reveal Email/Phone |
6 | Director IT | Reveal Email/Phone |
7 | Senior Finance Director | Reveal Email/Phone |
8 | Senior Director, CMC and Project Lead | Reveal Email/Phone |
9 | Co-Founder & Chief Business Officer | Reveal Email/Phone |
10 | Senior Research Director | Reveal Email/Phone |
Evox Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $6.1M | 69 | -13% | $16.5M | N/A |
#2 | $264.2M | 1850 | -1% | N/A | N/A |
#3 | $51.9M | 401 | -10% | $12.6M | N/A |
#4 | $22.5M | 205 | -39% | $63.8M | N/A |
#5 | $1.1M | 21 | -19% | $781.7K | N/A |
#6 | $21.3M | 190 | 33% | N/A | N/A |
#7 | $11.9M | 117 | 10% | N/A | N/A |
#8 | $3.8M | 46 | -10% | N/A | N/A |
#9 | $8.8M | 86 | -16% | N/A | N/A |
#10 | $2.5M | 31 | -40% | N/A | N/A |
What Is Evox Therapeutics?
Evox Therapeutics is harnessing and engineering the natural trafficking capabilities of extracellular vesicles to develop an entirely novel class of biotherapeutics. By combining groundbreaking exosome technology from well-renowned Oxford University and the Karolinska Institutet – the home of the Nobel Prize – we aim to revolutionise the treatment of a broad range of severe disease, with profound implications for human health. Based in Oxford, UK, Evox Therapeutics was founded in 2016 by Professor Matthew Wood of Oxford University, Assistant Professor Samir EL Andaloussi and Dr Per Lundin of the Karolinska Institutet, to capitalise on foundational intellectual property springing from the groundbreaking exosome research carried out in these two world-leading labs. Backed by Oxford Sciences Innovation and with a driven multidisciplinary team, Evox is building an exosome powerhouse focusing on the development of a modular platform for clinical translation of a broad range of exosome-based therapeutics. Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.
keywords:N/A$169.2M
Total Funding
132
Number of Employees
$13.5M
Revenue (est)
-13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Evox Therapeutics News
... LLC, EV Therapeutics, Inc., Evox Therapeutics Ltd, Exogenus Therapeutics, Invitrx Therapeutics, Inc., Organicell Regenerative Medicine,...
Before joining Evox, he was Executive Director, Process Development at Autolus Therapeutics plc, where he led late-stage CMC activities for the...
Before joining Evox, he was previously executive director of Process Development at Autolus Therapeutics plc. Prior to that, Jones held several...
Evox Therapeutics has raised £69.2 million in a Series C led by Redmile Group. The British startup modifies exosomes to facilitate targeted drug delivery for severe diseases with limited treatment options. The new capital will be used to develop its therapeutics pipeline and fund clinical trials ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $38.3M | 132 | 6% | N/A |
#2 | $29.3M | 133 | 4% | N/A |
#3 | $20M | 133 | 6% | N/A |
#4 | $28.1M | 134 | -10% | N/A |
#5 | $7.5M | 134 | 10% | N/A |